Table 2.

Regimens for second-line chemotherapy.

Regimens	Cytotoxic doublet or triplet with conventional approved biologics (n = 28)	Other regimens (n = 20)	Study drugs including BRAF inhibitors ( n = 4)	p value
	Cytotoxic doublet plus bevacizumab (n = 23)Cytotoxic doublet + anti-EGFR (n = 3) FOLFOXIRI + bevacizumab (n = 2)	Anti-EGFR + irinotecan (n = 4) Anti-EGFR monotherapy (n = 4) Cytotoxic doublet (n = 4) Irinotecan + bevacizumab (n = 2) Antimicrotubule agents (n = 1) Capecitabine + bevacizumab (n = 1) Irinotecan monotherapy (n = 1) FL + bevacizumab (n = 1) Regorafenib (n = 1) Trifluridine/tipiracil (n = 1)	Anti-EGFR + BRAF inhibitor + MEK inhibitor (n = 3) Anti-EGFR + BRAF inhibitor (n = 1)
ECOG PS 0-1/2	26/2	15/5	4/0	0.17
LDH <240/⩾240	16/12	9/11	3/1	0.58
GPS 0/1/2	15/7/5	7/4/8	2/2/0	0.27

Anti-EGFR, anti-epidermal growth factor receptor; ECOG PS, Eastern Cooperative Oncology Group performance status; FL, 5-FU/leucovorin; FOLFOXIRI, 5-FU/leucovorin+oxaliplatin+irinotecan; GPS, Glasgow Prognostic Score; LDH, lactate dehydrogenase.